Researchers from the Mayo Clinic in Rochester, Minnesota, discovered that an FDA-approved treatment for certain cancers of the blood may significantly reduce the growth of triple-negative breast cancers – even tumors that are resistant to chemotherapy.
Triple-negative breast cancer is often aggressive and difficult to treat. According to the Mayo researchers, their study suggests decitabine (5-aza-2'-deoxycytidine) may be effective against a specific subset of triple-negative breast cancers that contain certain proteins.
This research, part of the ongoing Breast Cancer Genome-Guided Therapy study involving cancer cells from breast cancer patients treated with chemotherapy, showed that, when DNA methyl transferase proteins were present, decitabine slowed the growth of triple-negative breast cancer. This effect was achieved at low therapeutic doses, resulting in less toxicity, allowing the drug to be used for a longer period, and improving its effectiveness.
Sourced from: The Journal of Clinical Investigation